<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genmab A/s — News on 6ix</title>
<link>https://6ix.com/company/genmab-as</link>
<description>Latest news and press releases for Genmab A/s on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genmab-as" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836228d78dffbe2df142109.webp</url>
<title>Genmab A/s</title>
<link>https://6ix.com/company/genmab-as</link>
</image>
<item>
<title>Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-first-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-net-sales-of-darzalexr-daratumumab-for-first-quarter-of-2026</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from</description>
</item>
<item>
<title>Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer</title>
<link>https://6ix.com/company/genmab-as/news/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-sr-in-combination-with-bevacizumab-in-advanced-ovarian-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-sr-in-combination-with-bevacizumab-in-advanced-ovarian-cancer</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients</description>
</item>
<item>
<title>Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab</title>
<link>https://6ix.com/company/genmab-as/news/constitution-of-the-board-of-directors-in-genmab-as-and-grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/constitution-of-the-board-of-directors-in-genmab-as-and-grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab-1</guid>
<pubDate>Thu, 19 Mar 2026 18:21:00 GMT</pubDate>
<description>Company AnnouncementCOPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 5,213 restricted stock units and 4,485 warrants to the employees of the Company and the Company’s subsidiaries.Each restricted stock unit is awarded cost-free and pr</description>
</item>
<item>
<title>Correction to Company Announcement No. 13 of March 2, 2026</title>
<link>https://6ix.com/company/genmab-as/news/correction-to-company-announcement-no-13-of-march-2-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/correction-to-company-announcement-no-13-of-march-2-2026-1</guid>
<pubDate>Mon, 02 Mar 2026 21:53:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52</description>
</item>
<item>
<title>Genmab to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/genmab-as/news/genmab-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 15:27:00 GMT</pubDate>
<description>Media ReleaseCOPENHAGEN, Denmark; February 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:</description>
</item>
<item>
<title>Genmab Publishes 2025 Annual Report</title>
<link>https://6ix.com/company/genmab-as/news/genmab-publishes-2025-annual-report-160100071</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-publishes-2025-annual-report-160100071</guid>
<pubDate>Tue, 17 Feb 2026 16:01:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the</description>
</item>
<item>
<title>Grant of Restricted Stock Units and Warrants to Employees in Genmab</title>
<link>https://6ix.com/company/genmab-as/news/grant-restricted-stock-units-warrants-174900002</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/grant-restricted-stock-units-warrants-174900002</guid>
<pubDate>Thu, 29 Jan 2026 17:49:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the da</description>
</item>
<item>
<title>Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-net-sales-darzalexr-daratumumab-2025-2026-01-21</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-net-sales-darzalexr-daratumumab-2025-2026-01-21</guid>
<pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
<description>Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J,</description>
</item>
<item>
<title>Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-topline-results-epcoritamab-183100673</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-topline-results-epcoritamab-183100673</guid>
<pubDate>Fri, 16 Jan 2026 18:31:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, January 16, 2026--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment</description>
</item>
<item>
<title>Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence</title>
<link>https://6ix.com/company/genmab-as/news/genmab-partners-anthropic-accelerate-research-and-development-through-agentic</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-partners-anthropic-accelerate-research-and-development-through-agentic</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to</description>
</item>
<item>
<title>Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/genmab-as/news/genmab-present-44th-annual-j-125800432</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-present-44th-annual-j-125800432</guid>
<pubDate>Mon, 05 Jan 2026 12:58:00 GMT</pubDate>
<description>Media ReleaseCOPENHAGEN, Denmark; January 5, 2026Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco at 3:45 PM PST / 6:45 PM EST on January 13, 2026, 12:45 AM CET on January 14, 2026. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-presentations. About Genmab Genmab is an international biotechnol</description>
</item>
<item>
<title>Genmab Portfolio Prioritization Update</title>
<link>https://6ix.com/company/genmab-as/news/genmab-portfolio-prioritization-update-2025-12-29</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-portfolio-prioritization-update-2025-12-29</guid>
<pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
<description>Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact</description>
</item>
<item>
<title>Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-completion-tender-offer-outstanding-common-shares-merus-nv-and-0</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-completion-tender-offer-outstanding-common-shares-merus-nv-and-0</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction</description>
</item>
<item>
<title>Genmab to Hold 2025 R&D Update and ASH Data Review Meeting</title>
<link>https://6ix.com/company/genmab-as/news/genmab-hold-2025-r-d-070000009</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-hold-2025-r-d-070000009</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2025.open-exchange.net/registration. An archive of the webcast will be ava</description>
</item>
<item>
<title>Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-new-data-phase-1b-2-epcorer-cll-1-highlighting-potential-epcoritamab</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-new-data-phase-1b-2-epcorer-cll-1-highlighting-potential-epcoritamab</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),</description>
</item>
<item>
<title>Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma</title>
<link>https://6ix.com/company/genmab-as/news/genmab-presents-pivotal-phase-3-125000176</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-presents-pivotal-phase-3-125000176</guid>
<pubDate>Sun, 07 Dec 2025 12:50:00 GMT</pubDate>
<description>Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R2 aloneEPKINLY + R2 was recently approved by the U.S. Food and Drug Administration as the first and only bispecific-based therapy for follicular lymphoma in the second-line settingResults of EPC</description>
</item>
<item>
<title>Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma</title>
<link>https://6ix.com/company/genmab-as/news/genmab-presents-pivotal-phase-3-data-epcorer-fl-1-trial-demonstrating-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-presents-pivotal-phase-3-data-epcorer-fl-1-trial-demonstrating-clinical</guid>
<pubDate>Sun, 07 Dec 2025 05:00:00 GMT</pubDate>
<description>Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically</description>
</item>
<item>
<title>Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-data-multiple-clinical-trials-showing-treatment-fixed-duration</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-data-multiple-clinical-trials-showing-treatment-fixed-duration</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients</description>
</item>
<item>
<title>Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes</title>
<link>https://6ix.com/company/genmab-as/news/genmab-announces-closing-private-offering-200300019</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/genmab-announces-closing-private-offering-200300019</guid>
<pubDate>Wed, 03 Dec 2025 20:03:00 GMT</pubDate>
<description>Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offering</description>
</item>
<item>
<title>Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons</title>
<link>https://6ix.com/company/genmab-as/news/transactions-shares-linked-securities-genmab-212400962</link>
<guid isPermaLink="true">https://6ix.com/company/genmab-as/news/transactions-shares-linked-securities-genmab-212400962</guid>
<pubDate>Mon, 01 Dec 2025 21:24:00 GMT</pubDate>
<description>Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading</description>
</item>
</channel>
</rss>